NICE recommends tepotinib as the first oral MET inhibitor treatment as an option for adult patients with advanced NSCLC with METex14 skipping alterations - ecan
Tepmetko Treatment for Non Small Cell Lung Cancer - CancerConnect
MET TKIs in METex14+ NSCLC: Tepotinib - Downloadable Slidesets - MET Inhibition in NSCLC - Oncology - Clinical Care Options
טוויטר \ NatureRevClinOncol בטוויטר: "MET inhibitor tepotinib, like capmatinib, seems to have good activity in METexon14-altered advanced-stage NSCLC #ASCO19 #LCSM https://t.co/qKqnwgzFo5"
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations | NEJM
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial -
c-Met inhibitor - Wikipedia
Ivy Elkins on Twitter: "#Tepotinib in patient derived xenografts from #NSCLC brain metastases resulted in tumor regression, including complete responses. Potentially promising for patients with brain metastases with #METamp drivers. #AACR20 #lcsm @
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
The effect of tepotinib on c-MET, β-catenin, ERK, and c-MYC protein... | Download Scientific Diagram
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance | Future Oncology
MET Exon 14 Skipping in NSCLC | TEPMETKO® (tepotinib) HCP
Tepotinib for MET Exon 14 Skipping Mutations in NSCLC
TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
Tepotinib - Wikipedia
Oncology Data Advisor - Tepotinib Approved for MET-Altered Non-Small Cell Lung Cancer
MET Inhibitors Active in Advanced NSCLC | MedPage Today
MET Exon 14 Skipping in NSCLC | TEPMETKO® (tepotinib) HCP
Therapeutics: tepotinib for lung cancer
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations - ScienceDirect
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases - Lung Cancer
Safety of Tepotinib in Patients with MET Exon 14 Skipping NSCLC and Recommendations for Management - Clinical Lung Cancer
